Intellia Therapeutics, Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. 87 Item 6. Exhibits The following exhibits are incorporated by reference or filed as part of this report. 10.1# Amendment No. 1, dated May 30, 2020, to the License and Collaboration Agreement, dated April 11, 2016, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (1) 10.2 Stock Purchase Agreement, dated May 30, 2020, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (1) 10.3† Corporate Bonus Plan, effective April 3, 2020. (2) 31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (2) 31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (2) 32.1 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, by John M. Leonard, M.D., President and Chief Executive Officer of the Company, and Glenn Goddard, Executive Vice President, Chief Financial Officer of the Company. (2) 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. (1) 101.SCH Inline XBRL Taxonomy Extension Schema Document. (1) 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. (1) 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. (1) 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. (1) 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. (1) 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*) (1) # Certain information in this exhibit was omitted by means of redacting a portion of the text and replacing it with “[***]”. The Registrant has determined that the omitted information (i) is not material and (ii) would be competitively harmful if publicly disclosed. † Indicates a management contract or any compensatory plan, contract or arrangement. (1) Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No. 001-37766) filed with the Securities and Exchange Commission on June 1, 2020. (2) Filed with this Quarterly Report on Form 10-Q. (3) The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. 88 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 6, 2020 INTELLIA THERAPEUTICS, INC. By: /s/ John M. Leonard John M. Leonard, M.D. President and Chief Executive Officer (Principal Executive Officer) By: /s/ Glenn G. Goddard Glenn G. Goddard Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) 89